Most significantly, the Company reported in June, 2008, that animals treated
with its anti-HIV lead drug candidate exhibited survival time superior to that
of animals treated with the standard three drug oral cocktail called HAART.
These studies employed the well established SCID-Hu Thy/Liv mouse model and
were conducted by KARD Scientific, Inc. The Company plans to perform additional
studies to obtain further detailed information regarding the effect of the nanoviricide
drug candidates on HIV in vivo.
NanoViricides, Inc. has reported in May, 2008, that its anti-EKC (epidemic
keratoconjunctivitis) drug candidate exhibited excellent clinical improvement
in an ophthalmic adenovirus infection animal model of this disease. These studies
were conducted by scientists at the Feinstein Institute of Medical Research
(FIMR), part of the North Shore-LIJ Health System. These studies were presented
by the FIMR scientists at the 42nd annual meeting of the Ocular Microbiology
and Immunology Group (OMIG) in Atlanta, Georgia, in November 2008. In addition,
evaluation of our ophthalmic anti-herpes nanoviricide drug candidates will begin
shortly at a renowned School of Veterinary Medicine in the US.
The Company further reports satisfactory progress in its anti-Rabies program.
These studies are continuing at the US Centers for Diseases Control and Prevention
The Company is presently in discussions with an independent research facility
to perform anti-H5N1 animal studies with the Company’s drug candidates
that were highly successful against H5N1 Clade 1 and Clade 2 in cell cultures.
These nanoviricides were also found to be highly effective against common influenza
(H1N1) in animal models.
The Company has previously reported positive results for its Ebola program.
The first part of the program consisted of cell culture studies of the effect
of nanoviricides against Ebola virus. Several nanoviricide drug candidates showed
very high efficacy against Ebola in these studies. These studies were conducted
by scientists at the United States Army Medical Research Institute for Infectious
Diseases (USAMRIID). Subsequently, the Company was invited to submit a grant
application to the TMTI program of the Department of Defense (DoD) and did so
this January. The objective of the grant application is to further develop both
the Ebola and Dengue programs of the Company. The DoD is interested in further
development of our broad-spectrum nanoviricides in order to minimize stockpiling
costs while still achieving high efficacies against a broad range of viruses.
The Company previously reported that it has signed certain agreements regarding
further development of its eye drug candidate. In addition, several other potential
collaboration partners have expressed a strong interest in pursuing co-development
opportunities for the Company’s other drug candidates. The Company is
actively pursuing these opportunities.
“We have attained strong positive achievements in the past twelve months
in all of our drug development programs,” said Eugene Seymour, MD, MPH,
CEO of the Company, adding, “We are confident that we will achieve further
successes in our drug development and commercialization programs during the
next calendar year as well.”